AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Sagimet Biosciences Inc.
Video analysis: SGMT
All videosNo video analysis for this stock yet. Request one from our team.
News: SGMT
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have assigned a buy recommendation to
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026.
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet's Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company's Series A common stock be granted on August 17, 2026 to the newly hired employees.
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executives said during a Canaccord Genuity discussion.
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here).
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution.
